Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Avantis International Equity ETF (AVDE)

Avantis International Equity ETF (AVDE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family American Century
  • Assets Under Management 6,674,176,000
  • Shares Outstanding, K 92,800
  • 60-Month Beta 0.94
  • Price/Earnings ttm 0.09
  • Annual Dividend & Yield 2.02 (2.81%)
  • Most Recent Dividend 0.850 on 12/17/24
  • Management Fee 0.23%

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 22.04%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
66.77 +7.71%
on 04/22/25
72.60 -0.94%
on 05/21/25
+5.87 (+8.89%)
since 04/21/25
3-Month
58.56 +22.82%
on 04/07/25
72.60 -0.94%
on 05/21/25
+6.31 (+9.62%)
since 02/21/25
52-Week
58.56 +22.82%
on 04/07/25
72.60 -0.94%
on 05/21/25
+6.68 (+10.24%)
since 05/21/24

Most Recent Stories

More News
Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish

Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize daratumumab....

GMAB : 20.52 (+0.93%)
AVDE : 71.92 (-0.46%)
FBT : 160.84 (-2.16%)
Novo Nordisk Warns Against Counterfeit Ozempic In US: Retail’s Unmoved

The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517.

APIE : 31.99 (-0.53%)
NVO : 68.20 (unch)
AVDE : 71.92 (-0.46%)
Novo Nordisk’s Controlling Shareholder Novo Holdings Reports Record Total Income, Investment Returns In 2024: Retail Stays Bullish

The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its investment...

APIE : 31.99 (-0.53%)
NVO : 68.20 (unch)
AVDE : 71.92 (-0.46%)
Novo Nordisk Stock Slips After BofA, Morgan Stanley Slash Price Targets – But Retail Goes Contrarian

Bank of America analysts said Novo Nordisk might miss first-quarter estimates. According to TheFly, they expect the company to lower its full-year sales guidance from 16%-24% at constant exchange rates...

NVO : 68.20 (unch)
AVDE : 71.92 (-0.46%)
Novo Nordisk Signs $2B Deal For Obesity Drug With Chinese Biotech: Retail Sentiment Improves

Novo Nordisk will obtain exclusive worldwide rights to develop, manufacture, and commercialize the drug UBT251, while United Biotechnology will, however, retain the rights to the drug in mainland China,...

APIE : 31.99 (-0.53%)
NVO : 68.20 (unch)
AVDE : 71.92 (-0.46%)
Sony Stock Surges After Q3 Earnings Beat, Raised Outlook: Retail’s Not Convinced

For full-year 2024, Sony expects revenue to be about JPY 13.2 trillion ($876 billion), 4% higher than its previous outlook.

SONY : 24.89 (-3.53%)
APIE : 31.99 (-0.53%)
AVDE : 71.92 (-0.46%)
Toyota Downgraded After Second Straight Profit Drop, But Stock Climbs As Annual Outlook Improves: Retail Stays Optimistic

Toyota also announced plans to establish a wholly owned company in Shanghai to develop and produce Lexus BEVs and batteries.

FVD : 44.43 (-1.49%)
APIE : 31.99 (-0.53%)
AVDE : 71.92 (-0.46%)
TM : 184.47 (-1.01%)
BP, Kosmos Energy Stocks In Spotlight After First Gas Flow From GTA Phase 1 Project: Retail Turns Bullish

Once commissioned, GTA Phase 1 is expected to produce around 2.3 million tonnes of liquefied natural gas (LNG) annually. 

DFIV : 41.87 (-0.45%)
AVDE : 71.92 (-0.46%)
BP : 28.88 (-1.10%)
KOS : 1.6400 (-2.38%)
Toyota Stock Catches Retail's Eye After Report Of Auto Giant's Aim To Double Equity Returns

The news boosted Toyota’s shares by nearly 6% in Tokyo trading earlier in the day.

FVD : 44.43 (-1.49%)
APIE : 31.99 (-0.53%)
AVDE : 71.92 (-0.46%)
TM : 184.47 (-1.01%)
Sony Stock Jumps Pre-Market As Profit Booms Nearly 70%: Retail Buzz Builds

Despite selling only 3.8 million PlayStation 5 units this quarter — down from 4.9 million a year ago — Sony raised its annual profit forecast.

SONY : 24.89 (-3.53%)
APIE : 31.99 (-0.53%)
AVDE : 71.92 (-0.46%)
AVIV : 60.87 (-0.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Fund Summary

The Avantis International Equity ETF seeks long-term capital appreciation investing in a broad set of companies of all market capitalizations across non-U.S. developed countries and is designed to increase expected returns by overweighting securities we believe to be trading at lower valuations with...

See More

Top 10 Holdings

Name % Holdings
N/A 0.84%
N/A 0.84%
Novo Nordisk A/S ADR 0.81%
Novo Nordisk A/S ADR 0.81%
Royal Dutch Shell Plc ADR 0.78%
Royal Dutch Shell Plc ADR 0.78%
RHEINMETALL AG COMMON STOCK 0.74%
RHEINMETALL AG COMMON STOCK 0.74%
HSBC Holdings Plc ADR 0.68%
HSBC Holdings Plc ADR 0.68%

See More

Key Turning Points

3rd Resistance Point 73.11
2nd Resistance Point 72.85
1st Resistance Point 72.39
Last Price 71.92
1st Support Level 71.67
2nd Support Level 71.41
3rd Support Level 70.94

See More

52-Week High 72.60
Last Price 71.92
Fibonacci 61.8% 67.23
Fibonacci 50% 65.58
Fibonacci 38.2% 63.92
52-Week Low 58.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »